Eli Lilly Raises Sales Outlook on Surging Zepbound and Mounjaro Demand
Eli Lilly lifted its full-year sales forecast after Zepbound and Mounjaro posted another strong quarter, with the CEO signaling major obesity market growth ahead.
Eli Lilly raised its annual sales outlook Wednesday after blockbuster obesity drug Zepbound and diabetes treatment Mounjaro delivered surging revenue in the third quarter, reinforcing the pharmaceutical giant's dominant position in the booming weight-loss drug market.
Chief Executive Officer David Ricks indicated the company sees substantial room for further expansion, describing the obesity treatment market as capable of "dramatic" growth. His comments signal that Lilly views current demand as only the early stages of a much larger commercial opportunity, as millions of Americans remain undiagnosed or untreated for obesity and related metabolic conditions.
Read more Amazon Stock Falls Despite Bold New AWS Cloud Forecast →
The back-to-back quarterly gains for both Zepbound and Mounjaro underscore how GLP-1 receptor agonist therapies have reshaped Lilly's financial trajectory in a relatively short period. The two drugs, which share the same active ingredient tirzepatide, have rapidly become the company's primary revenue engines, driving investor enthusiasm and competitive pressure across the broader pharmaceutical sector.
The upgraded sales guidance reflects management's confidence that supply constraints — which hampered earlier growth — are easing, allowing the company to meet robust consumer and prescriber demand more effectively. The obesity drug race has attracted intense scrutiny from payers, regulators, and rivals, yet Lilly appears positioned to sustain its momentum heading into the final quarter of the year.
Continue reading at US Top News and Analysis.
